List of Excipients in Branded Drug NEVIRAPINE EXTENDED RELEASE

Generic Drugs Containing NEVIRAPINE EXTENDED RELEASE

Company	Ingredient	NDC	Excipient
Alvogen Inc	nevirapine	47781-109	HYPROMELLOSE
Alvogen Inc	nevirapine	47781-109	LACTOSE MONOHYDRATE
Alvogen Inc	nevirapine	47781-109	ZINC STEARATE

What are the Most Frequently-Used Excipients in NEVIRAPINE EXTENDED RELEASE?

# Of NDCs	Excipient
1	HYPROMELLOSE
1	LACTOSE MONOHYDRATE
1	ZINC STEARATE

Nevirapine Extended-Release Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Nevirapine extended release is a once-daily antiretroviral tablet built around a hydrophilic polymer matrix. The core commercial opportunity is a lower-cost generic or regional product that preserves 400 mg once-daily dosing, reliable release control, and acceptable tablet size. The main technical barriers are dose-dumping control, bioequivalence against the reference product, consistent matrix manufacture, and management of nevirapine’s established rash and hepatotoxicity risks.

What is nevirapine extended release?

Nevirapine extended release, marketed in the United States as Viramune XR, contains 400 mg of nevirapine in a once-daily tablet. It is a non-nucleoside reverse transcriptase inhibitor used with other antiretroviral agents for treatment of HIV-1 infection in adults and pediatric patients meeting the applicable age and dosing requirements.[1]

The product uses a prolonged-release tablet rather than a conventional immediate-release tablet. Patients generally begin therapy with immediate-release nevirapine during a 14-day lead-in period before switching to extended-release treatment. The lead-in reduces the risk of serious nevirapine-associated skin reactions and supports safer dose initiation.[1]

Product characteristic	Nevirapine extended release
Active ingredient	Nevirapine
Dosage form	Film-coated extended-release tablet
Strength	400 mg
Administration	Once daily
Therapeutic class	Non-nucleoside reverse transcriptase inhibitor
Reference product	Viramune XR
Manufacturer	Boehringer Ingelheim
Release technology	Hydrophilic matrix tablet
Key safety issues	Severe rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatotoxicity
Generic development route	Abbreviated New Drug Application, subject to FDA requirements

What excipients are used in nevirapine extended-release tablets?

The Viramune XR tablet uses a conventional hydrophilic matrix approach. The U.S. prescribing information identifies hypromellose, lactose monohydrate, povidone, magnesium stearate, colloidal silicon dioxide, and coating components among the inactive ingredients.[1]

Hypromellose controls extended release

Hypromellose, also called hydroxypropyl methylcellulose or HPMC, is the principal release-controlling excipient. After contact with gastrointestinal fluid, the polymer hydrates and forms a gel layer around the tablet. Drug release occurs through a combination of diffusion through the hydrated matrix and gradual matrix erosion.

The commercial value of HPMC selection lies in controlling:

• Initial burst release
• Duration of drug release
• Tablet-to-tablet variability
• Sensitivity to compression force
• Sensitivity to particle size and viscosity grade
• Food and gastrointestinal fluid effects

A generic developer must select a polymer grade and concentration that reproduce the reference product’s release profile across multiple dissolution conditions. A formulation that releases nevirapine too rapidly can create a regulatory failure and may increase safety concerns associated with excessive exposure.

Lactose monohydrate supports tablet mass and processing

Lactose monohydrate is used as a diluent and contributes to powder flow and tablet compactability. It can help achieve a commercially practical tablet weight when the active pharmaceutical ingredient represents a large share of the core.

The main development considerations are lactose particle size, moisture content, compatibility with the active ingredient, and the selected manufacturing process. Direct compression can reduce process steps, but wet granulation may provide better content uniformity and flow if the nevirapine powder has poor handling properties.

Povidone functions as a binder

Povidone supports granule strength and tablet integrity. Its concentration affects hardness, friability, disintegration of the hydrated matrix, and release kinetics. Excessive binder levels can produce a dense tablet and slow drug release. Insufficient binder can cause capping, lamination, or mechanical damage during coating and packaging.

Magnesium stearate requires controlled lubrication

Magnesium stearate improves ejection from the tablet press. Over-lubrication can create hydrophobic coating on powder particles, reducing wetting and altering dissolution. Mixing time, lubricant concentration, and order of addition should therefore be controlled as critical process variables.

Colloidal silicon dioxide improves flow

Colloidal silicon dioxide can improve powder flow and reduce process variability. Its performance depends on surface area, concentration, mixing energy, and the moisture characteristics of the formulation.

Film-coating excipients support identification and handling

The film coating can contain hypromellose, polyethylene glycol or macrogol, titanium dioxide, and iron oxide pigments. Coating provides tablet identification, protects the core, improves swallowability, and supports packaging-line performance. It should not materially alter the extended-release profile.

How should a generic developer design the excipient platform?

The most defensible strategy is a robust matrix formulation rather than a highly complex proprietary delivery system. The target should be a formulation that reproduces the reference product’s in vitro release profile while minimizing excipient complexity and manufacturing cost.

Recommended formulation architecture

A development program would typically evaluate:

1. A high-viscosity HPMC matrix system for release control.
2. Lactose or a comparable filler for tablet mass and compaction.
3. Povidone or an equivalent binder for mechanical strength.
4. Low-level colloidal silicon dioxide for flow.
5. Magnesium stearate at the minimum concentration needed for ejection.
6. A conventional protective film coat.

The formulation should be screened against several HPMC viscosity grades and polymer concentrations. The target profile should be assessed under immediate-release discriminatory conditions as well as prolonged-release conditions. Testing should include pH ranges representing the stomach and intestinal tract, agitation speeds, media volume, and fed-state conditions.

Which critical quality attributes matter most?

The primary quality attributes are:

Attribute	Commercial and regulatory relevance
Assay	Confirms labeled nevirapine content
Content uniformity	Important for a high-strength tablet
Dissolution profile	Demonstrates release control and supports bioequivalence
Related substances	Controls degradation and process impurities
Tablet hardness	Affects handling and dissolution
Friability	Controls packaging and transport losses
Water content	Can affect HPMC hydration and stability
Coating weight	Supports identification and protection
Stability profile	Determines shelf life and packaging requirements

A developer should treat dissolution as a formulation and process endpoint, not merely as a finished-product test. Compression force, granule porosity, lubricant distribution, and tablet dimensions can materially change release performance.

What manufacturing and intellectual-property barriers affect nevirapine extended release?

The core manufacturing barrier is reproducible control of release over the product shelf life. HPMC matrices can show changes in hydration and dissolution behavior when particle size, polymer viscosity, compression force, or storage humidity changes.

Manufacturing barriers

Key process risks include:

• Segregation of nevirapine and excipient particles
• Variable granule density
• Inconsistent polymer distribution
• Over-lubrication
• Compression-force drift
• Coating-induced tablet defects
• Moisture-driven changes in dissolution
• Packaging-related stability failures

A high-throughput commercial process should use process analytical technology for blend uniformity, tablet weight, compression force, and coating weight. High-barrier blister packaging or tightly controlled bottles may be necessary where moisture sensitivity affects release performance.

Patent barriers

The relevant intellectual-property review should cover four categories:

Patent category	Relevance to nevirapine extended release
Drug substance patents	Historical protection for nevirapine itself
Extended-release formulation patents	Potential protection for matrix composition or release profile
Manufacturing patents	Granulation, compression, coating, or process controls
Method-of-use patents	HIV treatment regimens, lead-in dosing, or patient populations

Nevirapine’s basic composition-of-matter protection is historical and does not represent the principal barrier for a present-day generic program. The more relevant questions are whether any formulation, process, or method-of-use claims remain enforceable in the target jurisdiction and whether those claims are listed or otherwise relevant to a regulatory filing.

For the United States, an applicant should review FDA’s Orange Book for current listed patents and exclusivity, then conduct a separate patent-family search across U.S., European, Indian, Chinese, Brazilian, and other commercially relevant jurisdictions. Formulation patents may have different expiration dates from the original active-ingredient patents.

When does nevirapine extended release lose exclusivity?

Viramune XR was approved by the FDA in 2011.[2] FDA approval alone does not establish the current enforceability of every related patent. Exclusivity analysis requires separation of regulatory exclusivity from patent term.

FDA exclusivity and Orange Book status

The principal regulatory questions are:

• Whether any exclusivity remains listed for Viramune XR
• Whether FDA has accepted or approved an ANDA for the 400 mg extended-release product
• Whether Orange Book-listed patents cover the product, formulation, or use
• Whether a Paragraph IV certification has been filed
• Whether litigation triggered a 30-month stay
• Whether a settlement agreement limits launch timing

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The brand company may file an infringement action within the statutory period, potentially creating a 30-month stay of ANDA approval under the Hatch-Waxman framework.[3]

The commercial assessment should not assume that an unlisted formulation patent is irrelevant. It may still affect litigation, manufacturing freedom to operate, licensing value, or launch strategy even if it does not delay FDA approval through the Orange Book mechanism.

What is the FDA regulatory status of nevirapine extended release?

The FDA-approved product is an extended-release tablet used as part of combination antiretroviral therapy. FDA labeling requires the 14-day immediate-release lead-in before extended-release dosing in applicable patients. The tablet must be swallowed whole and should not be crushed, chewed, or divided because those actions can compromise controlled release.[1]

A generic applicant should expect the regulatory program to focus on:

• Pharmaceutical equivalence
• Extended-release dissolution similarity
• Bioequivalence under relevant fasting and fed conditions
• Dose proportionality or strength-related justification
• Safety labeling consistency
• Demonstration that tablet manipulation does not create an unacceptable release profile
• Stability through the proposed shelf life

Because nevirapine has clinically important hypersensitivity and hepatic safety risks, the generic label must remain consistent with the reference product unless FDA authorizes a justified difference.

What commercial opportunities exist for nevirapine extended release?

The principal opportunity is cost-efficient supply in markets where HIV treatment programs value once-daily dosing but have limited budgets. Nevirapine is older than many newer antiretroviral agents, so commercial success depends on manufacturing cost, procurement access, and regimen compatibility rather than premium pricing.

Generic extended-release tablets

A generic 400 mg once-daily product can compete through:

• Lower manufacturing cost
• Regional registration in high-volume HIV markets
• Supply contracts with public-sector procurement agencies
• Co-packaged use with compatible antiretroviral products
• Improved availability where the branded product is discontinued or constrained

The formulation should avoid unnecessary proprietary excipients that raise cost or complicate regulatory bridging. A common excipient platform can support multiple manufacturing sites if the developer controls polymer grade, particle-size specifications, and dissolution performance.

Contract manufacturing and licensing

The most practical licensing targets are:

• Established generic antiretroviral manufacturers
• Regional firms with HIV registration infrastructure
• Public-health suppliers
• Companies with high-volume modified-release tablet capacity
• Manufacturers holding local approvals for immediate-release nevirapine

A licensing deal may combine drug-product know-how, regulatory dossiers, and territorial rights. The value of the package depends on whether the licensor owns a defensible formulation patent, has completed bioequivalence work, or only provides a conventional formulation concept.

Fixed-dose combination potential

Nevirapine extended release is less attractive for a new fixed-dose combination than newer once-daily antiretrovirals because of its safety profile, drug-interaction burden, and declining clinical preference in many treatment guidelines. A combination product would face additional risks involving:

• Different release requirements for each active ingredient
• Chemical compatibility
• Dose-ratio constraints
• Manufacturing segregation
• More complex bioequivalence studies
• Potential mismatch with current treatment guidelines

The more credible opportunity is a stand-alone generic product or a regional supply arrangement, not a premium next-generation combination.

How does nevirapine extended release compare with newer HIV medicines?

Attribute	Nevirapine extended release	Newer integrase inhibitor regimens
Dosing	Once daily	Often once daily
Technology	Conventional modified-release tablet	Immediate-release tablet or advanced formulation
Cost potential	High for generic supply	Variable; often higher for newer products
Resistance barrier	Lower	Generally higher for preferred integrase inhibitors
Safety concerns	Rash and hepatotoxicity	Agent-specific metabolic, renal, and weight considerations
Commercial positioning	Low-cost or legacy-regimen access	Preferred modern treatment in many settings
Patent opportunity	Mainly generic and regional	More active formulation and combination patent estates
Biosimilar risk	None	None for small-molecule products

Nevirapine extended release does not face biosimilar competition because it is a chemically synthesized small molecule. The relevant competitive threats are generic immediate-release nevirapine, alternative once-daily antiretroviral regimens, and procurement substitution.

What generic launch scenarios exist for nevirapine extended release?

Scenario 1: Direct U.S. ANDA launch

This scenario requires a viable reference-product pathway, acceptable patent certification, successful bioequivalence, and sufficient commercial demand. The opportunity may be limited if the reference product has low sales or if the active market has shifted toward newer therapies.

Scenario 2: Emerging-market launch

A regional launch can be more attractive where HIV programs still use nevirapine-containing regimens and procurement agencies prioritize price. Registration requirements, local bioequivalence standards, and tender access become the main commercial determinants.

Scenario 3: Authorized or licensed supply

A licensed product can reduce development and litigation costs if the agreement provides formulation know-how, regulatory data, or a permitted launch date. Territorial rights and minimum-volume commitments would determine the economic value.

Scenario 4: Immediate-release substitution

A manufacturer may instead pursue immediate-release nevirapine, which is technically simpler but does not reproduce the adherence and dosing proposition of the extended-release product. It competes in a different segment and may not substitute directly for once-daily treatment.

How strong is the patent estate for nevirapine extended release?

The active-ingredient patent estate is likely to be commercially exhausted in major markets because nevirapine has been marketed for decades. The remaining risk is narrower and product-specific: extended-release composition claims, manufacturing claims, and method-of-use claims.

Patent strength should be assessed using four factors:

1. Claim scope: whether claims cover the entire matrix platform or only narrow excipient ratios.
2. Remaining term: whether expiration occurs before regulatory approval or commercial launch.
3. Enablement and written description: whether the claims adequately support the full scope.
4. Litigation history: whether similar claims survived validity or infringement challenges.

A conventional HPMC, lactose, povidone, and lubricant formulation may be difficult to protect broadly unless the patent includes a defined release profile, unexpected pharmacokinetic result, or specific manufacturing limitation. Trade secrets involving granulation, compression, and dissolution control may have greater practical value than a narrow excipient patent.

Key Takeaways

• Nevirapine extended release is a 400 mg once-daily hydrophilic matrix tablet marketed as Viramune XR.
• HPMC is the principal release-controlling excipient; lactose, povidone, magnesium stearate, and colloidal silicon dioxide support manufacturability.
• The critical technical target is a stable dissolution profile without dose dumping.
• FDA development requires attention to extended-release bioequivalence, fed and fasting studies, stability, and consistent safety labeling.
• Nevirapine has no biosimilar risk because it is a small-molecule drug.
• Commercial opportunity is strongest in low-cost generic and regional procurement markets.
• The main patent risks are formulation, manufacturing, and method-of-use claims rather than the original nevirapine compound patent.
• Fixed-dose combination development is less attractive because of safety, interaction, and shifting HIV treatment preferences.
• A generic developer should prioritize polymer-grade control, dissolution robustness, low-cost manufacturing, and freedom-to-operate review.

FAQs

Is nevirapine extended release still commercially attractive?

Yes, primarily as a low-cost generic or regional product. Its attractiveness depends on tender demand, reference-product availability, current treatment guidelines, and the ability to manufacture a reliable 400 mg matrix tablet at low cost.

Can nevirapine extended release be crushed or split?

No. The extended-release tablet should be swallowed whole because crushing, chewing, or splitting can alter drug release.[1]

Which excipient is most important in nevirapine extended release?

Hypromellose is the most important because it forms the hydrated matrix that controls nevirapine release. Its viscosity grade, concentration, particle size, and distribution are central formulation variables.

Does nevirapine extended release have biosimilar competition?

No. Biosimilar pathways apply to biological products. Nevirapine is a chemically synthesized small molecule and is subject to generic-drug competition.

What is the strongest commercial differentiation for a generic product?

The strongest differentiation is usually dependable supply, low cost, regulatory approvals in high-demand markets, and a dissolution profile that supports robust bioequivalence. Novel excipients alone are unlikely to create a durable premium position.

References

1. U.S. Food and Drug Administration. (2011). Viramune XR (nevirapine extended-release tablets) prescribing information. U.S. Department of Health and Human Services.

2. U.S. Food and Drug Administration. (2011). Drugs@FDA: Viramune XR application history. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services.